Thursday, June 28, 2018



The long-awaited labels have arrived; equipment is today being deployed in the format that our new bottles require; and staff is on notice that SHIPPING BEGINS MONDAY! 

Couldn't have better news to kick off this 3rd quarter of 2018!!  As our FIRST QUARTER of Bocannaco operations!


Funny Video, Happy Dog, Jumping, Gif


No more paper apps will be accepted after June 30, which is THIS SATURDAY!  

We need time to conclude all paper apps and be sure that everything is processed correctly -- BECAUSE  your websites will be LIVE shortly after that,  both for signing up Distributors and for folks ordering Product!  This can be done by credit card or checks.

HOWEVER, Founders will continue to be  accepted by paper app and checks ONLY -- as is currently the procedure, until the cut-off date of August 31, 2018, or 300 shares claimed, whichever comes first.



From Bocannaco Founders Pool Member Marlene Zamora

FYI... my 83 yr old dad was rushed to ER for sepsis. When I’m at hospital I was sneaking doc's CBD into his mouth without his dr or nurses seeing it. He was discharged from hospital in less than 7 days. He even made it to my daughter’s 8th grade graduation just being discharged less then 48 hrs. Admitted to hospital May 23rd. Discharged  and attended his granddaughter’s 8th grade graduation on June 8th. Said we had to go “stealth” with the CBD. Couldn’t let the medical staff know we were giving it to him:) Yes--- Actually it  was less than 2 weeks in the hospital with full blown sepsis!


Monday, June 25, 2018

Bocannaco VIDEO LINKS and Malia!

VIDEO LINKS: Feel free to share! Product should be to all Founders next week. -Avita


Bocannaco Call featuring Malia Young Brohn, click here.

(Malia starts at 3:37)

Sunday, June 24, 2018

Bocannaco story of the week!

Special Guest Bocannaco Founders Pool Member Malia Young-Brohn will share her CBD oil story of the week!  Be sure to listen:

Bocannaco Monday Night Call:  6 pm Pacific time,  June 25, 2018

Dial (515) 739-1030     Access Code 319-289-214#



Thursday, June 21, 2018

Jeff 'splains it

Bocannaco Founders Pool Member Jeff Verdugo explains Bocannaco last night to Fresno guests:

To watch video, click on 'Read More' for rest of screen.
Part 1:

Wednesday, June 20, 2018

All you need to send people is this video

Exactly 4 months ago today we had our first group to meet at Dr. Lawrence’s office and lab in L.A.

Barb and I invited them to come meet Doc and verify what we were kicking around in starting a brand new MLM. 

It is amazing  what has been accomplished in 4 months and what is astonishing to us is how many of you see the same incredible opportunity we all did. 

All our legal work done and approved:
Websites and back office up and ready to go live. 
Product and bottles at Doc’s office and just waiting on labels.  
All new equipment installed for shipping product and this department  ready to ship when we get green light. 

We already have regular meetings happening across USA now- without a product. 

“Can You Imagine” when our products start rolling out??!

This video is all you need to send folks!

Kudos to Anthony Huff, video-maker extraordinaire, for the awesome trio of Bocannaco videos to date.  Such talent!

Monday, June 18, 2018


Tonight, Bocannaco Monday Night Call (details on yesterday's blog)

Tuesday, Oakhurst, CA   6pm   Yosemite Bank Conference Room

Wednesday, Fresno, CA  7pm  Marie Callender's -- Blackstone (River Park)

Thursday, 6:30 and 8 pm SHARP  Meeting at 242 Deertrail Drive,  Dyer, Indiana @ Mr. Kosinskis' home

Sunday, June 17, 2018

Bocannaco: What's the diff?

Bocannaco Monday Night Call:  6 pm Pacific time,  June 18, 2018

Dial (515) 739-1030     Access Code 319-289-214#




Researchin' away!

Anxiety Relief Without The High? New Studies On CBD, A Cannabis Extract

(Source:  NPR 

As more states legalize marijuana, there's growing interest in a cannabis extract — cannabidiol, also known as CBD.
It's marketed as a compound that can help relieve anxiety — and, perhaps, help ease aches and pains, too.
Part of the appeal, at least for people who don't want to get high, is that CBD doesn't have the same mind-altering effects as marijuana, since it does not contain THC, the psychoactive component of the plant.

"CBD has gotten a lot of buzz," Ferry says, as he displays an array of CBD products, including capsules and bottles of liquid CBD oil that users dispense under the tongue with a dropper.

"There's a lot of confusion about how it [CBD] works and what it does exactly," Ferry says.
Researchers now are trying to nail down CBD's effects.

"I think there's good evidence to suggest that CBD could be an effective treatment of anxiety and addiction" and other disorders, says Dr. Esther Blessing, a psychiatrist and researcher at New York University. "But we need clinical trials to find out."
So far, evidence of the substance's anti-anxiety effect comes from animal research and from very small, short-term human studies that suggest CBD exhibits anti-inflammatory and anti-anxiety properties.

These preliminary findings piqued Blessing's interest. For instance, she points to a 2011 study of a few dozen people, some of whom had social anxiety disorder, who were asked to speak in front of a large audience. Researchers compared anxiety levels in people after they took CBD, compared to those who got the placebo or nothing at all. (The participants didn't know if they'd been given the drug or the placebo.)

And what did the scientists find? "People who took CBD reported significantly less anxiety" compared to those who got the placebo, Blessing says. "It's really interesting."

Now, with funding from the National Institutes of Health, Blessing and group of collaborators are about to begin a clinical trial to test whether CBD can help people with post-traumatic stress disorder who also have moderate or severe alcohol use disorder.
During the study, 50 participants with PTSD coexisting with alcohol use disorder will be given either 400 milligrams of CBD daily, or a placebo. The goal is to see if the participants who take CBD end up drinking less and whether this leads to an improvement in PTSD symptoms. The participants will be given a pharmaceutical-grade CBD, which is more reliable in strength and purity than the supplements that are currently available for sale to the public.
Another Phase 2 clinical trial (to test efficacy and side effects) is exploring whether CBD might help prevent relapse in opioid abusers by reducing craving for the drug. The study's led by Yasmin Hurd, a neuroscientist who directs the Addiction Institute at the Mount Sinai School of Medicine.
Hurd has been trying to rally other top scientists to study CBD's effects and potential benefits in the treatment of substance abuse.
It may seem counterintuitive that a component of marijuana could be useful in treating addiction to another drug. But Blessing says using CBD is very different from using marijuana. Though CBD is extracted from cannabis, it does not lead to altered perception and cognition.

"Drugs can be non-psychoactive and still have an effect on the brain," Blessing says. "CBD does have an effect on the brain, but it seems to affect the brain in possibly medicinal ways."

Results from Blessing study are a few years off. But in the meantime, just last week, a panel of advisors to the Food and Drug Administration recommended approval of the first pharmaceutical grade CBD, called Epidiolex, to treat severe seizure disorders in children. This could open the door to more research to approve its use in other disorders.

Dr. Robert Carson is a pediatric neurologist at Vanderbilt University who has evaluated the effectiveness of CBD supplements in kids with seizures. He says the supplements can be beneficial for these children. However, he says, if the FDA follows its advisory panel's advice and approves a pharmaceutical-grade CBD drug, that would open up a new treatment option by delivering a high-quality, consistent dose of CBD.

"One of the main caveats I tell my patients who use a CBD supplement is that we cannot guarantee what's in it," Carson explains. "We can't guarantee the consistency."
Supplements aren't regulated as strictly as pharmaceuticals, and can vary widely from bottle to bottle or brand to brand.


Anyone who has watched the newest Bocannaco video knows that Bocannaco's finest hemp oil is rigidly consistent because the plants are grown -- on Doc's farm -- from CULTIVARS.  Not from seeds!  

What's the diff?

You REALLY have to watch that video -- it explains all the reasons much better than I can!

If you haven't seen it yet, click here: 


And, yes, like you we're waiting moment by moment for the floodgates to open, the websites to go live, and shipping to COMMENCE!  Might be a little like this:  !!

Related image

Saturday, June 16, 2018

Bocannaco and the Local/Global Reach

The reach of CBD is global; but the focus of Bocannaco is local.

 Local to each Founder and Distributor!

Below are three articles sent from you in just the last few days.



From Bocannaco Founders Bonus Pool Member Randy Orloff, source:

UK changes course, allows epileptic boy to use cannabis oil

Updated 11:49 am, Saturday, June 16, 2018

LONDON (AP) — The British government changed course Saturday in a case concerning cannabis oil, saying an epileptic boy can be treated with it after his mother said he needed it to survive severe seizures.
Home Secretary Sajid Javid said he has agreed to urgently issue a license to allow Billy Caldwell, a 12-year-old from Northern Ireland, to be treated with the oil. He said his decision was based on advice from senior doctors who say that Caldwell, who was hospitalized overnight in London, faces a medical emergency.
Javid said the British government's immediate priority was to make sure Caldwell receives "the most effective treatment possible in a safe way."


Cannabidiol as an Emergent Therapeutic Strategy for Lessening the Impact of Inflammation on Oxidative Stress


Oxidative stress with reactive oxygen species generation is a key weapon in the arsenal of the immune system for fighting invading pathogens and to initiate tissue repair. If excessive or unresolved, however, immune-related oxidative stress can initiate further increasing levels of oxidative stress that cause organ damage and dysfunction. Targeting oxidative stress in these various diseases therapeutically has proven more problematic than first anticipated given the complexities and perversity of both the underlying disease and the immune response. However, growing evidence suggests that the endocannabinoid system, which includes the CB1 and CB2 G protein-coupled receptors and their endogenous lipid ligands, may be an area that is ripe for therapeutic exploitation. In this context, the related nonpsychotropic cannabinoid cannabidiol, which may interact with the endocannabinoid system, but has actions that are distinct, offers promise as a prototype for anti-inflammatory drug development. This review discusses recent studies suggesting that cannabidiol may have utility in treating a number of human diseases and disorders now known to involve activation of the immune system and associated oxidative stress, as a contributor to their etiology and progression. These include rheumatoid arthritis, types I and II diabetes, atherosclerosis, Alzheimer’s disease, hypertension, the metabolic syndrome, ischemia-reperfusion injury, depression, and neuropathic pain.


And this excerpt from IWANTMYCBD03292017:


More later....!